160 related articles for article (PubMed ID: 20456401)
1. Clinical applicability of T-cell interferon-a release assay for tumour necrosis factor-a inhibitor therapy in severe psoriasis.
Chiang YZ; Panting K; Dever B; Parslew RA
Clin Exp Dermatol; 2011 Jan; 36(1):39-41. PubMed ID: 20456401
[TBL] [Abstract][Full Text] [Related]
2. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
[TBL] [Abstract][Full Text] [Related]
3. Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China.
Li CR; Mao QX; Chen M; Jia WX; Yao X; Feng SY; Jia H; Gong JQ; Yang XY
Drug Des Devel Ther; 2015; 9():5591-4. PubMed ID: 26508833
[TBL] [Abstract][Full Text] [Related]
4. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test.
Laffitte E; Janssens JP; Roux-Lombard P; Thielen AM; Barde C; Marazza G; Panizzon RG; Saurat JH
Br J Dermatol; 2009 Oct; 161(4):797-800. PubMed ID: 19659473
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
Chiu HY; Hsueh PR; Tsai TF
Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the use of the interferon-γ response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-α therapy: a prospective head-to-head cross-sectional study.
Martyn-Simmons CL; Mee JB; Kirkham BW; Groves RW; Milburn HJ
Br J Dermatol; 2013 May; 168(5):1012-8. PubMed ID: 23278714
[TBL] [Abstract][Full Text] [Related]
7. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
[TBL] [Abstract][Full Text] [Related]
9. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
[TBL] [Abstract][Full Text] [Related]
10. Can ELISpot replace the tuberculin skin test for latent tuberculosis?
Greveson K
Br J Nurs; 2009 Nov 12-25; 18(20):1248-54. PubMed ID: 20081663
[TBL] [Abstract][Full Text] [Related]
11. Severe psoriasis with positive tuberculosis test and treatment with biologic therapy: a case report.
Skroza N; Proietti I; Bernardini N; La Viola G; Nicolucci F; Tolino E; Zuber S; Potenza C
Cutis; 2012 Sep; 90(3):120-2. PubMed ID: 23094309
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers.
Saraceno R; Specchio F; Chiricozzi A; Sarmati L; Amicosante M; Chimenti MS; Chimenti S
Expert Opin Biol Ther; 2014 Feb; 14(2):151-6. PubMed ID: 24303977
[TBL] [Abstract][Full Text] [Related]
13. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an IFN-gamma assay in the diagnosis of latent tuberculosis in patients with psoriasis in a highly endemic setting.
de Andrade Lima E; de Andrade Lima M; de Lorena VM; de Miranda Gomes Y; Lupi O; Benard G
Acta Derm Venereol; 2011 Oct; 91(6):694-7. PubMed ID: 21629971
[TBL] [Abstract][Full Text] [Related]
15. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
16. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
[TBL] [Abstract][Full Text] [Related]
17. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population.
Ponce de Leon D; Acevedo-Vasquez E; Alvizuri S; Gutierrez C; Cucho M; Alfaro J; Perich R; Sanchez-Torres A; Pastor C; Sanchez-Schwartz C; Medina M; Gamboa R; Ugarte M
J Rheumatol; 2008 May; 35(5):776-81. PubMed ID: 18398944
[TBL] [Abstract][Full Text] [Related]
18. The 'either test positive' strategy for latent tuberculous infection before anti-tumour necrosis factor treatment.
Jung YJ; Lee JY; Jo KW; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee KH; Lee SD; Kim WS; Kim DS; Shim TS
Int J Tuberc Lung Dis; 2014 Apr; 18(4):428-34. PubMed ID: 24670697
[TBL] [Abstract][Full Text] [Related]
19. Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis.
Martin J; Walsh C; Gibbs A; McDonnell T; Fearon U; Keane J; Codd MB; Dodd J; Veale D; Fitzgerald O; Bresnihan B
Ann Rheum Dis; 2010 Jan; 69(1):181-5. PubMed ID: 19176545
[TBL] [Abstract][Full Text] [Related]
20. Combined use of a TST and the T-SPOT®.TB assay for latent tuberculosis infection diagnosis before anti-TNF-α treatment.
Jung YJ; Lyu J; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee KH; Lee SD; Kim WS; Kim DS; Shim TS
Int J Tuberc Lung Dis; 2012 Oct; 16(10):1300-6. PubMed ID: 22863375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
